샘플 요청 목록

 카트 문의
시장보고서
상품코드
1809419

지도형 위축 시장(2025-2035년)

Geographic Atrophy Market Report 2025-2035
발행일: | 리서치사: Visiongain | 페이지 정보: 영문 323 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 지도형 위축 시장 규모는 2035년까지 CAGR 13.1%를 나타낼 것으로 예측됩니다.

지도형 위축의 유병률 증가

지도형 위축(GA)은 노화와 밀접하게 관련되어 있으며 주로 60세 이상의 사람들에게 영향을 미칩니다. 따라서 고령화는 미래 수요를 높이는 가장 강력한 요인 중 하나로 여겨지고 있습니다. 2024년에 발표된 JAMA(Journal of the American Medical Association)의 연구에 의하면, 연령 황반변성의 세계적인 환자 수는 현재의 1억 9,600만명에서 2040년에는 2억 8,800만명으로 증가할 것으로 예측되고 있습니다.

유병률이 증가함에 따라 효과적인 치료법의 필요성이 점점 커지고 있습니다. 바이오의약품 기업은 고령 환자를 위한 내구성을 높이고, 안전성을 개선하고, 사용의 용이성을 중시한 치료법의 개발을 진행하고 있습니다. 페그세타코플랜과 아바신 캅타도 페골과 같은 최근 승인된 약물은 인구 고령화가 급속히 진행되는 고소득 지역에서 이미 강한 보급을 보이고 있습니다. 이러한 인구동태의 변화는 임상적 의의뿐만 아니라 상업적으로도 큰 의미를 가지고 있습니다. 제약 회사는 접근하기 쉬운 치료법을 설계하고 환자 지원 프로그램을 구축함으로써 증가하는 취약한 환자층에 대응할 필요가 있습니다.

현행 치료의 제한적인 효과는 시장 성장을 억제

현재 승인된 보체 억제제의 치료 효과는 여전히 논의의 대상이 되고 있습니다. 이 약들은 병변의 진행을 늦추는 효과를 보여 주지만, 그 효과는 제한적이며 반드시 시력 기능의 상당한 개선으로 이어지지는 않습니다. 주요 3상 시험(OAKS 및 DERBY)의 결과에서 1-2년간 병변 확대의 평균 억제율은 약 16-22%를 나타내 나타났으며, 위약군과의 차이는 시간이 지남에 따라 명확해졌습니다. 그러나 교정 시력과 같은 중요한 기능적 결과는 일관된 개선을 얻지 못했습니다.

또한, 안전에 대한 우려가 보급을 어렵게 하고 있습니다. 시판 후 조사나 등록 데이터에서는 치료 환자의 일부에 안내 염증이나 망막 염증 등의 사례가 보고되고 있어, 이것에 의해 모니터링의 강화나 환자 적격성의 엄격화가 요구되고 있습니다. 게다가 유리체내 주사를 빈번히 실시하는 부담도 겹쳐, 광범위한 이용에의 의욕을 저하시키고 있습니다.

실제로, 현재의 치료는 일정한 유용성을 가지면서 그 효과는 제한적이며, 사용은 신중하게 선택된 환자층으로 제한됩니다. 망막 질환 전반의 의료 현장에서는 안전성 및 기능적 결과에 대한 장기적이고 강력한 데이터를 얻을 때까지 이러한 치료법을 주류로 채택하기가 어려운 상황입니다.

미국 통상관세가 세계의 지도형 위축 시장에 미치는 영향

미국의 통상관세는 GA 치료제 시장에 간접적인 영향을 미칠 수 있습니다. 이는 치료제 및 그 투여 장치의 제조 비용을 증가시키기 때문입니다. GA치료제 등의 완성된 바이오의약품은 의료상 불가결하기 때문에 고관세의 대상외가 되는 경우가 많습니다만, 그 제조에 불가결한 무균 충전·마무리 장치, 특수 유리 바이알, 주사기 등의 업스트림 부재는 관세의 영향을 받는 나라로부터 조달되는 것이 적지 않습니다. 이러한 비용 상승은 전체 생산 비용을 증가시키고 결과적으로 치료 가격 상승으로 이어질 수 있습니다. 이미 고가격대에서 제공되고 있는 GA 치료제에 있어서는 약간의 비용 증가로도 보험자와의 협상을 어렵게 하고, 환자의 접근을 제한하고, 비용에 민감한 의료 시스템에서의 보급을 늦추는 위험이 있습니다.

본 보고서에서는 세계의 지도형 위축 시장을 조사했으며, 시장 개요, 시장성장에 미치는 영향요인 및 시장 기회 분석, 시장 규모 추이와 예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 보고서 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
  • 영향 분석
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • 미국 관세 : 세계의 지도형 위축 시장에 미치는 영향은?
  • 규제 프레임워크
  • 신흥 시장과 메가 트렌드
  • Porter's Five Forces 분석
  • PEST 분석

제4장 지도형 위축 시장 분석 : 유형별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 초점 GA
  • 다초점 GA
  • 융합성 황반위축증
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제5장 지도형 위축 시장 분석 : 약제별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 페그세타코플란(SYFOVRE)
  • 아바신캡타드 페골(IZERVAY)
  • 틴라레반트(LBS-008)
  • 길데우레티놀(ALK-001)
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제6장 지도형 위축 시장 분석 : 투여 경로별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 유리체강 내 투여 경로
  • 정맥 내 투여 경로
  • 기타
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제7장 지도형 위축 시장 분석 : 유통 채널별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 병원 약국
  • 소매 약국
  • 전자상거래 약국
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제8장 지도형 위축 시장 분석 : 연령층별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 60세 미만
  • 60세 이상
  • 70세 이상
    • 시장 규모 추이와 예측 : 지역별
    • 시장 점유율 : 지역별

제9장 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추이와 예측 : 지역별

제10장 북미의 지도형 위축 시장 분석

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 시장 규모 추이와 예측 : 국가별
  • 시장 규모 추이와 예측 : 유형별
  • 시장 규모 추이와 예측 : 약제별
  • 시장 규모 추이와 예측 : 투여 경로별
  • 시장 규모 추이와 예측 : 유통 채널별
  • 시장 규모 추이와 예측 : 연령층별
  • 미국
  • 캐나다

제11장 유럽의 지도형 위축 시장 분석

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 시장 규모 추이와 예측 : 국가별
  • 시장 규모 추이와 예측 : 유형별
  • 시장 규모 추이와 예측 : 약제별
  • 시장 규모 추이와 예측 : 투여 경로별
  • 시장 규모 추이와 예측 : 유통 채널별
  • 시장 규모 추이와 예측 : 연령층별
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 러시아
  • 네덜란드
  • 덴마크
  • 기타

제12장 아시아태평양의 지도형 위축 시장 분석

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 시장 규모 추이와 예측 : 국가별
  • 시장 규모 추이와 예측 : 유형별
  • 시장 규모 추이와 예측 : 약제별
  • 시장 규모 추이와 예측 : 투여 경로별
  • 시장 규모 추이와 예측 : 유통 채널별
  • 시장 규모 추이와 예측 : 연령층별
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타

제13장 라틴아메리카의 지도형 위축 시장 분석

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 시장 규모 추이와 예측 : 국가별
  • 시장 규모 추이와 예측 : 유형별
  • 시장 규모 추이와 예측 : 약제별
  • 시장 규모 추이와 예측 : 투여 경로별
  • 시장 규모 추이와 예측 : 유통 채널별
  • 시장 규모 추이와 예측 : 연령층별
  • 브라질
  • 멕시코
  • 기타

제14장 중동 및 아프리카의 지도형 위축 시장 분석

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추이와 예측
  • 시장 규모 추이와 예측 : 국가별
  • 시장 규모 추이와 예측 : 유형별
  • 시장 규모 추이와 예측 : 약제별
  • 시장 규모 추이와 예측 : 투여 경로별
  • 시장 규모 추이와 예측 : 유통 채널별
  • 시장 규모 추이와 예측 : 연령층별
  • GCC 국가
  • 남아프리카
  • 기타

제15장 기업 프로파일

  • 경쟁 환경
  • 전략적 전망
  • Alkeus Pharmaceuticals, Inc.
  • Bausch Lomb
  • Ionis Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • F. Hoffmann-La Roche Ltd.
  • Apellis Pharmaceuticals
  • AstraZeneca
  • Johnson & Johnson
  • Aviceda Therapeutics
  • Annexon, Inc.
  • Stealth BioTherapeutics Inc.
  • Belite Bio,N￠Inc.
  • Cognition Therapeutics

제16장 결론과 제안

  • Visiongain의 결론
  • 참가 기업에 대한 제안
KTH 25.09.17

The global Geographic Atrophy market is projected to grow at a CAGR of 13.1% by 2035.

The Geographic Atrophy Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Prevalence of Geographic Atrophy

Geographic atrophy (GA) is closely linked with ageing, predominantly affecting people aged 60 and above. As a result, population ageing stands out as one of the strongest drivers of future demand. A 2024 Journal of the American Medical Association (JAMA) study projects that global cases of age-related macular degeneration will rise from 196 million today to 288 million by 2040.

As prevalence rises, the need for effective therapies is intensifying. Biopharmaceutical companies are responding by advancing treatments designed with greater durability, improved safety, and enhanced usability for elderly patients. Uptake of recently approved drugs such as pegcetacoplan and avacincaptad pegol has already been strong across high-income regions, where ageing populations are expanding fastest. Beyond clinical impact, the demographic shift also represents a commercial imperative: drug makers must adapt by designing accessible therapies and building patient support programmes to serve a growing, vulnerable population segment.

Limited Efficacy of Current Therapies is Hindering the Market Growth

The therapeutic impact of currently approved complement inhibitors for geographic atrophy (GA) remains the subject of ongoing debate. While these drugs have demonstrated the ability to slow lesion growth, the effect is modest and does not consistently translate into meaningful improvements in functional vision. Results from the pivotal OAKS and DERBY Phase 3 trials showed average reductions in GA lesion enlargement of around 16-22% over one to two years, with clearer separation from sham groups emerging over time. However, improvements in key functional outcomes, such as best-corrected visual acuity, were not reliably achieved.

Safety concerns further complicate adoption. Post-marketing surveillance and registry data have reported clusters of intraocular inflammation and other retinal inflammatory events in treated patients, prompting tighter monitoring requirements and more selective patient eligibility. Coupled with the ongoing burden of frequent intravitreal injections, these factors have dampened enthusiasm for broad use.

In practice, current therapies provide meaningful yet limited benefits, with uptake largely confined to carefully chosen patient populations. For the wider retinal community, stronger long-term data on safety and functional outcomes remain essential before these treatments can achieve mainstream adoption.

What would be the Impact of US Trade Tariffs on the Global Geographic Atrophy Market ?

U.S. trade tariffs have the potential to indirectly influence the global market for geographic atrophy (GA) therapies by raising production costs for treatments and their delivery devices. While finished biopharmaceuticals such as GA drugs are often exempt from high tariffs due to their medical necessity, the upstream components essential to their manufacture-such as sterile fill-finish equipment, specialised glass vials, and injection devices-are frequently sourced from tariff-affected countries. Any increase in costs for these inputs drives up overall production expenses, which can, in turn, translate into higher treatment prices. Given that GA therapies already carry premium price points, even marginal cost increases risk complicating payer negotiations, restricting patient access, and slowing adoption in cost-sensitive healthcare systems.

The implications extend well beyond the U.S. Pharmaceutical companies typically operate integrated supply chains spanning multiple regions, and while large multinationals with diversified sourcing can absorb or offset tariff risks, smaller biotech firms dependent on single-source suppliers may face significant margin pressures. For these companies, partnerships with larger players may become a necessity. Over time, persistent tariffs could prompt more investment in localised manufacturing and supplier diversification, reshaping competitive dynamics and altering how quickly GA therapies can scale globally.

In response, companies may fast-track investments in domestic production sites or shift parts of their supply chains to tariff-neutral regions to mitigate exposure. This restructuring could elevate the role of emerging markets such as Asia Pacific and Latin America as alternative manufacturing hubs. However, such transitions demand considerable capital and time, potentially slowing innovation or delaying the availability of new therapies in the short term. In the longer run, the interaction between tariffs, localisation, and global demand is likely to redefine how GA treatments are priced, distributed, and adopted worldwide.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the geographic atrophy market evolving?
  • What is driving and restraining the geographic atrophy market?
  • How will each geographic atrophy submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
  • How will the market shares for each geographic atrophy submarket develop from 2025 to 2035?
  • What will be the main driver for the overall market from 2025 to 2035?
  • Will leading geographic atrophy markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the geographic atrophy projects for these leading companies?
  • How will the industry evolve during the period between 2025 and 2035? What are the implications of geographic atrophy projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the geographic atrophy market?
  • Where is the geographic atrophy market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the geographic atrophy market today, and over the next 10 years:

  • Our 323-page report provides 130 tables and 190 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2035 and other analysis reveal commercial prospects
  • In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analysis, with business outlooks and developments.
  • Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising geographic atrophy prices and recent developments.

Segments Covered in the Report

  • Type
  • Focal GA
  • Multifocal GA
  • Confluent GA
  • Drugs
  • Pegcetacoplan (SYFOVRE)
  • Avacincaptad pegol (IZERVAY)
  • Tinlarebant (LBS-008)
  • Gildeuretinol (ALK-001)
  • Others
  • Route of Administration
  • Intravitreal Route
  • Intravenous Route
  • Others
  • Age Group
  • Below 60 Years
  • Above 60 Years
  • Above 70 Years
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Geographic Atrophy Market, 2025 to 2035, with a focus on this segment of these companies' operations.

  • Leading companies profiled in the report
  • Alkeus Pharmaceuticals, Inc.
  • Annexon, Inc.
  • Apellis Pharmaceuticals
  • Astellas Pharma Inc.
  • AstraZeneca
  • Aviceda Therapeutics
  • Bausch + Lomb
  • Belite Bio™ Inc.
  • Boehringer Ingelheim International GmbH
  • Cognition Therapeutics
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals
  • Johnson & Johnson
  • Santen Pharmaceutical Co., Ltd.
  • Stealth BioTherapeutics

Overall world revenue for Geographic Atrophy Market, 2025 to 2035 in terms of value the market will surpass US$7,400.0 million in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Geographic Atrophy Market, 2025 to 2035 report help you?
  • In summary, our 320+ page report provides you with the following knowledge:
  • Revenue forecasts to 2035 for Geographic Atrophy Market, 2025 to 2035, with forecasts for type, drugs, route of administration, age group, and distribution channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2035 for five regional and 19 key national markets - See forecasts for the Geographic Atrophy Market, 2025 to 2035 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Geographic Atrophy Market, 2025 to 2035.
  • Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Geographic Atrophy Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Expanding Clinical Trial Pipeline for GA Treatments
      • 3.3.1.2 Rising Ageing Population Worldwide is Driving the Demand for GA Drugs
      • 3.3.1.3 Growing Prevalence of Geographic Atrophy
      • 3.3.1.4 Approval of Novel and Advanced Drugs
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Treatment Costs
      • 3.3.2.2 Limited Efficacy of Current Therapies
      • 3.3.2.3 Regulatory and Reimbursement Hurdles Across Regions
      • 3.3.2.4 Low Awareness in Emerging and Low-income Markets
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Development of Oral and Less Invasive Therapies
      • 3.3.3.2 Growth Potential in Emerging Markets including Asia Pacific and Latin America
      • 3.3.3.3 Strategic M&A and Partnerships Among Market Players for Faster Innovation and Expansion
  • 3.4 U.S. Tariffs: What's the Impact on Global Geographic Atrophy Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
      • 3.4.2.5 Timeframe for Recovery
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Market Dynamics and Demand Recovery
      • 3.4.3.4 Policy and Funding Support
      • 3.4.3.5 Timeframe for Recovery
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on Geographic Atrophy Market
  • 3.5 Regulatory Framework
  • 3.6 Emerging Markets and Megatrends
  • 3.7 Porter's Five Forces Analysis
    • 3.7.1 Bargaining Power of Suppliers
    • 3.7.2 Bargaining Power of Buyers
    • 3.7.3 Competitive Rivalry
    • 3.7.4 Threat of Substitutes
    • 3.7.5 Threat of New Entrants
  • 3.8 PEST Analysis

4 Geographic Atrophy Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 Geographic Atrophy Market Size Estimation and Forecast by Type
  • 4.4 Focal GA
    • 4.4.1 Market Size by Region, 2025-2035 (US$ Million)
    • 4.4.2 Market Share by Region, 2025 & 2035 (%)
  • 4.5 Multifocal GA
    • 4.5.1 Market Size by Region, 2025-2035 (US$ Million)
    • 4.5.2 Market Share by Region, 2025 & 2035 (%)
  • 4.6 Confluent GA
    • 4.6.1 Market Size by Region, 2025-2035 (US$ Million)
    • 4.6.2 Market Share by Region, 2025 & 2035 (%)

5 Geographic Atrophy Market Analysis by Drugs

  • 5.1 Key Findings
  • 5.2 Drugs Segment: Market Attractiveness Index
  • 5.3 Geographic Atrophy Market Size Estimation and Forecast by Drugs
  • 5.4 Pegcetacoplan (SYFOVRE)
    • 5.4.1 Market Size by Region, 2025-2035 (US$ Million)
    • 5.4.2 Market Share by Region, 2025 & 2035 (%)
  • 5.5 Avacincaptad pegol (IZERVAY)
    • 5.5.1 Market Size by Region, 2025-2035 (US$ Million)
    • 5.5.2 Market Share by Region, 2025 & 2035 (%)
  • 5.6 Tinlarebant (LBS-008)
    • 5.6.1 Market Size by Region, 2025-2035 (US$ Million)
    • 5.6.2 Market Share by Region, 2025 & 2035 (%)
  • 5.7 Gildeuretinol (ALK-001)
    • 5.7.1 Market Size by Region, 2025-2035 (US$ Million)
    • 5.7.2 Market Share by Region, 2025 & 2035 (%)
  • 5.8 Others
    • 5.8.1 Market Size by Region, 2025-2035 (US$ Million)
    • 5.8.2 Market Share by Region, 2025 & 2035 (%)

6 Geographic Atrophy Market Analysis by Route of Administration

  • 6.1 Key Findings
  • 6.2 Route of Administration Segment: Market Attractiveness Index
  • 6.3 Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
  • 6.4 Intravitreal Route
    • 6.4.1 Market Size by Region, 2025-2035 (US$ Million)
    • 6.4.2 Market Share by Region, 2025 & 2035 (%)
  • 6.5 Intravenous Route
    • 6.5.1 Market Size by Region, 2025-2035 (US$ Million)
    • 6.5.2 Market Share by Region, 2025 & 2035 (%)
  • 6.6 Others
    • 6.6.1 Market Size by Region, 2025-2035 (US$ Million)
    • 6.6.2 Market Share by Region, 2025 & 2035 (%)

7 Geographic Atrophy Market Analysis by Distribution Channel

  • 7.1 Key Findings
  • 7.2 Distribution Channel Segment: Market Attractiveness Index
  • 7.3 Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
  • 7.4 Hospital Pharmacies
    • 7.4.1 Market Size by Region, 2025-2035 (US$ Million)
    • 7.4.2 Market Share by Region, 2025 & 2035 (%)
  • 7.5 Retail Pharmacies
    • 7.5.1 Market Size by Region, 2025-2035 (US$ Million)
    • 7.5.2 Market Share by Region, 2025 & 2035 (%)
  • 7.6 E-Commerce Pharmacies
    • 7.6.1 Market Size by Region, 2025-2035 (US$ Million)
    • 7.6.2 Market Share by Region, 2025 & 2035 (%)

8 Geographic Atrophy Market Analysis by Age Group

  • 8.1 Key Findings
  • 8.2 Age Group Segment: Market Attractiveness Index
  • 8.3 Geographic Atrophy Market Size Estimation and Forecast by Age Group
  • 8.4 Below 60 Years
    • 8.4.1 Market Size by Region, 2025-2035 (US$ Million)
    • 8.4.2 Market Share by Region, 2025 & 2035 (%)
  • 8.5 Above 60 Years
    • 8.5.1 Market Size by Region, 2025-2035 (US$ Million)
    • 8.5.2 Market Share by Region, 2025 & 2035 (%)
  • 8.6 Above 70 Years
    • 8.6.1 Market Size by Region, 2025-2035 (US$ Million)
    • 8.6.2 Market Share by Region, 2025 & 2035 (%)

9 Geographic Atrophy Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America Geographic Atrophy Market Analysis

  • 10.1 Key Findings
  • 10.2 North America Geographic Atrophy Market Attractiveness Index
  • 10.3 North America Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
  • 10.4 North America Geographic Atrophy Market Size Estimation and Forecast by Country
  • 10.5 North America Geographic Atrophy Market Size Estimation and Forecast by Type
  • 10.6 North America Geographic Atrophy Market Size Estimation and Forecast by Drugs
  • 10.7 North America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
  • 10.8 North America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
  • 10.9 North America Geographic Atrophy Market Size Estimation and Forecast by Age Group
  • 10.10 U.S. Geographic Atrophy Market Analysis
  • 10.11 Canada Geographic Atrophy Market Analysis

11 Europe Geographic Atrophy Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe Geographic Atrophy Market Attractiveness Index
  • 11.3 Europe Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
  • 11.4 Europe Geographic Atrophy Market Size Estimation and Forecast by Country
  • 11.5 Europe Geographic Atrophy Market Size Estimation and Forecast by Type
  • 11.6 Europe Geographic Atrophy Market Size Estimation and Forecast by Drugs
  • 11.7 Europe Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
  • 11.8 Europe Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
  • 11.9 Europe Geographic Atrophy Market Size Estimation and Forecast by Age Group
  • 11.10 Germany Geographic Atrophy Market Analysis
  • 11.11 UK Geographic Atrophy Market Analysis
  • 11.12 France Geographic Atrophy Market Analysis
  • 11.13 Italy Geographic Atrophy Market Analysis
  • 11.14 Spain Geographic Atrophy Market Analysis
  • 11.15 Russia Geographic Atrophy Market Analysis
  • 11.16 Netherlands Geographic Atrophy Market Analysis
  • 11.17 Denmark Geographic Atrophy Market Analysis
  • 11.18 Rest of Europe Geographic Atrophy Market Analysis

12 Asia Pacific Geographic Atrophy Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific Geographic Atrophy Market Attractiveness Index
  • 12.3 Asia Pacific Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
  • 12.4 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Type
  • 12.6 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Drugs
  • 12.7 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
  • 12.8 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
  • 12.9 Asia Pacific Geographic Atrophy Market Size Estimation and Forecast by Age Group
  • 12.10 Japan Geographic Atrophy Market Analysis
  • 12.11 China Geographic Atrophy Market Analysis
  • 12.12 India Geographic Atrophy Market Analysis
  • 12.13 Australia Geographic Atrophy Market Analysis
  • 12.14 South Korea Geographic Atrophy Market Analysis
  • 12.15 Rest of Asia Pacific Geographic Atrophy Market Analysis

13 Latin America Geographic Atrophy Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America Geographic Atrophy Market Attractiveness Index
  • 13.3 Latin America Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
  • 13.4 Latin America Geographic Atrophy Market Size Estimation and Forecast by Country
  • 13.5 Latin America Geographic Atrophy Market Size Estimation and Forecast by Type
  • 13.6 Latin America Geographic Atrophy Market Size Estimation and Forecast by Drugs
  • 13.7 Latin America Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
  • 13.8 Latin America Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
  • 13.9 Latin America Geographic Atrophy Market Size Estimation and Forecast by Age Group
  • 13.10 Brazil Geographic Atrophy Market Analysis
  • 13.11 Mexico Geographic Atrophy Market Analysis
  • 13.12 Rest of Latin America Geographic Atrophy Market Analysis

14 MEA Geographic Atrophy Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA Geographic Atrophy Market Attractiveness Index
  • 14.3 MEA Geographic Atrophy Market Size by Country, 2025, 2030 & 2035 (US$ Million)
  • 14.4 MEA Geographic Atrophy Market Size Estimation and Forecast by Country
  • 14.5 MEA Geographic Atrophy Market Size Estimation and Forecast by Type
  • 14.6 MEA Geographic Atrophy Market Size Estimation and Forecast by Drugs
  • 14.7 MEA Geographic Atrophy Market Size Estimation and Forecast by Route of Administration
  • 14.8 MEA Geographic Atrophy Market Size Estimation and Forecast by Distribution Channel
  • 14.9 MEA Geographic Atrophy Market Size Estimation and Forecast by Age Group
  • 14.10 GCC Geographic Atrophy Market Analysis
  • 14.11 South Africa Geographic Atrophy Market Analysis
  • 14.12 Rest of MEA Geographic Atrophy Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2024
  • 15.2 Strategic Outlook
  • 15.1 Alkeus Pharmaceuticals, Inc.
    • 15.1.1 Company Snapshot
    • 15.1.2 Company Overview
    • 15.1.3 Product Benchmarking
    • 15.1.4 Strategic Outlook
    • 15.1.5 SWOT Analysis
  • 15.2 Bausch + Lomb
    • 15.2.1 Company Snapshot
    • 15.2.2 Company Overview
    • 15.2.3 Financial Analysis
      • 15.2.3.1 Net Revenue, 2020-2024
      • 15.2.3.2 R&D, 2020-2024
      • 15.2.3.3 Business Market Shares, 2024
    • 15.2.4 Product Benchmarking
    • 15.2.5 Strategic Outlook
    • 15.2.6 SWOT Analysis
  • 15.3 Ionis Pharmaceuticals
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2020-2024
      • 15.3.3.2 R&D, 2020-2024
      • 15.3.3.3 Business Market Shares, 2024
    • 15.3.4 Product Benchmarking
  • 15.4 Santen Pharmaceutical Co., Ltd.
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2020-2024
      • 15.4.3.2 R&D, 2020-2024
    • 15.4.4 Product Benchmarking
    • 15.4.5 Strategic Outlook
  • 15.5 Astellas Pharma Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2020-2024
      • 15.5.3.2 R&D, 2020-2024
      • 15.5.3.3 Regional Market Shares, 2024
      • 15.5.3.4 Business Market Shares, 2024
    • 15.5.4 Product Benchmarking
    • 15.5.5 Strategic Outlook
    • 15.5.6 SWOT Analysis
  • 15.6 Boehringer Ingelheim International GmbH
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Financial Analysis
      • 15.6.3.1 Net Revenue, 2020-2024
      • 15.6.3.2 R&D, 2020-2024
      • 15.6.3.3 Regional Market Shares, 2024
      • 15.6.3.4 Business Market Shares, 2024
    • 15.6.4 Product Benchmarking
    • 15.6.5 Strategic Outlook
  • 15.7 F. Hoffmann-La Roche Ltd.
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Financial Analysis
      • 15.7.3.1 Net Revenue, 2020-2024
      • 15.7.3.2 R&D, 2020-2024
      • 15.7.3.3 Business Market Shares, 2024
    • 15.7.4 Product Benchmarking
    • 15.7.5 Strategic Outlook
  • 15.8 Apellis Pharmaceuticals
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Financial Analysis
      • 15.8.3.1 Net Revenue, 2020-2024
      • 15.8.3.2 R&D, 2020-2024
      • 15.8.3.3 Business Market Shares, 2024
    • 15.8.4 Product Benchmarking
    • 15.8.5 Strategic Outlook
    • 15.8.6 SWOT Analysis
  • 15.9 AstraZeneca
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Financial Analysis
      • 15.9.3.1 Net Revenue, 2020-2024
      • 15.9.3.2 R&D, 2020-2024
      • 15.9.3.3 Regional Market Shares, 2024
      • 15.9.3.4 Business Market Shares, 2024
    • 15.9.4 Product Benchmarking
    • 15.9.5 Strategic Outlook
  • 15.10 Johnson & Johnson
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Financial Analysis
      • 15.10.3.1 Net Revenue, 2020-2024
      • 15.10.3.2 R&D, 2020-2024
      • 15.10.3.3 Regional Market Shares, 2024
      • 15.10.3.4 Business Market Shares, 2024
    • 15.10.4 Product Benchmarking
  • 15.11 Aviceda Therapeutics
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Product Benchmarking
    • 15.11.4 Strategic Outlook
  • 15.12 Annexon, Inc.
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Financial Analysis
      • 15.12.3.1 R&D, 2020-2024
    • 15.12.4 Product Benchmarking
    • 15.12.5 Strategic Outlook
  • 15.13 Stealth BioTherapeutics Inc.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Product Benchmarking
    • 15.13.4 Strategic Outlook
  • 15.14 Belite Bio™ Inc.
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Financial Analysis
      • 15.14.3.1 R&D, 2020-2024
    • 15.14.4 Product Benchmarking
    • 15.14.5 Strategic Outlook
  • 15.15 Cognition Therapeutics
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Financial Analysis
      • 15.15.3.1 R&D, 2020-2024
    • 15.15.4 Product Benchmarking
    • 15.15.5 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제